SAB Biotherapeutics (NASDAQ:SABS) Announces Earnings Results, Misses Expectations By $0.15 EPS

SAB Biotherapeutics (NASDAQ:SABS) posted its earnings results on Tuesday. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.15), FiscalAI reports.

Here are the key takeaways from SAB Biotherapeutics’ conference call:

• SABBio said SAFEGUARD enrollment is on track, with Part A fully enrolled and Part B now actively enrolling across the U.S., Australia, New Zealand, the U.K. and Europe.
• The company received FDA written confirmation that C-peptide may be used as a surrogate endpoint for accelerated approval, which management described as a meaningful de-risking of the regulatory path.
• Phase I SAB-142 data continued to support the program, with management highlighting beta-cell preservation, T-cell exhaustion, and a favorable safety profile including no serum sickness and low or no immunogenicity.
• SABBio ended Q1 with $217.6 million in cash, cash equivalents and available-for-sale securities, which it says funds operations through 2028 and supports SAFEGUARD plus pre-commercial work.
• The company also signed a multi-year manufacturing agreement with Emergent BioSolutions to support process development and both clinical and commercial production ahead of a potential launch.

SAB Biotherapeutics Stock Performance

Shares of SAB Biotherapeutics stock traded up $0.05 during trading hours on Thursday, reaching $4.01. 59,345 shares of the stock traded hands, compared to its average volume of 646,686. SAB Biotherapeutics has a one year low of $1.60 and a one year high of $6.60. The company has a quick ratio of 9.46, a current ratio of 9.46 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $204.05 million, a price-to-earnings ratio of -1.87 and a beta of 0.55. The company has a 50 day moving average price of $3.86 and a 200 day moving average price of $3.82.

Key Stories Impacting SAB Biotherapeutics

Here are the key news stories impacting SAB Biotherapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating on SAB Biotherapeutics and increased its price target to $10, signaling continued confidence in the stock’s upside potential. Article Title
• Positive Sentiment: Zacks Research upgraded SAB Biotherapeutics from “strong sell” to “hold,” which may have helped improve near-term sentiment. Article Title
• Neutral Sentiment: HC Wainwright issued quarterly and long-term EPS estimates that remain negative, but imply the company expects losses to narrow over time, with FY2027 through FY2030 forecasts ranging from ($0.54) to ($0.42)/($0.43) per share. Article Title
• Negative Sentiment: The company’s most recent reported quarterly results missed estimates, posting EPS of ($0.35) versus the consensus expectation of ($0.20), which remains a drag on fundamentals. Article Title

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d+)” rating on shares of SAB Biotherapeutics in a report on Friday, April 10th. Zacks Research raised SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday. HC Wainwright lifted their price objective on SAB Biotherapeutics from $7.00 to $10.00 and gave the stock a “buy” rating in a report on Tuesday. Wall Street Zen cut shares of SAB Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. Finally, Chardan Capital raised their target price on shares of SAB Biotherapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, SAB Biotherapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $11.00.

Institutional Investors Weigh In On SAB Biotherapeutics

Several institutional investors have recently modified their holdings of the stock. ADAR1 Capital Management LLC increased its stake in SAB Biotherapeutics by 75.6% in the 4th quarter. ADAR1 Capital Management LLC now owns 26,344 shares of the company’s stock worth $99,000 after buying an additional 11,344 shares during the period. ExodusPoint Capital Management LP acquired a new stake in shares of SAB Biotherapeutics in the fourth quarter valued at about $322,000. OMERS ADMINISTRATION Corp purchased a new position in shares of SAB Biotherapeutics during the 4th quarter worth $157,000. Verition Fund Management LLC acquired a new stake in shares of SAB Biotherapeutics during the 4th quarter worth about $100,000. Finally, Marshall Wace LLP purchased a new stake in shares of SAB Biotherapeutics during the fourth quarter worth $884,000. 7.82% of the stock is owned by institutional investors.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.